Adjuvant therapy is associated with improved survival after curative resection for hilar cholangiocarcinoma: A multi‐institution analysis from the U.S. extrahepatic biliary malignancy consortium

Adjuvant therapy is associated with improved survival after curative resection for hilar... INTRODUCTIONCholangiocarcinoma accounts for 3% of gastrointestinal malignancies worldwide, with 3500 cases diagnosed per year in the United States, the majority of which (60‐80%) arise in the perihilar region. Unresectable disease has a dismal prognosis, with a median survival of less than 1 year. Margin negative R0 resection provides the only chance for long‐term cure. Despite this, resectable disease has a 5‐year survival between 20% and 50%. Adjuvant therapy (AT) has been advocated after resected hilar cholangiocarcinoma (HC) to improve outcomes.The role of AT for resected HC is a source of significant debate. Current National Comprehensive Cancer Network (NCCN) guidelines for AT in resected HC comment that more data are necessary in order to make firm conclusions. In two recent retrospective reviews of AT in biliary tract cancer (BTC), no survival benefit was found. Conversely, within the last 10 years three single center retrospective studies have demonstrated a survival benefit with AT in resected extrahepatic cholangiocarcinoma. In the only published phase III randomized trial of AT that included patients with HC, and in the recently completed phase III trial of gemcitabine plus oxaliplatin in BTC, there was no significant survival benefit noted.Herein, we sought to determine the role of AT http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Surgical Oncology Wiley

Loading next page...
 
/lp/wiley/adjuvant-therapy-is-associated-with-improved-survival-after-curative-kEUn17TST0
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0022-4790
eISSN
1096-9098
D.O.I.
10.1002/jso.24836
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONCholangiocarcinoma accounts for 3% of gastrointestinal malignancies worldwide, with 3500 cases diagnosed per year in the United States, the majority of which (60‐80%) arise in the perihilar region. Unresectable disease has a dismal prognosis, with a median survival of less than 1 year. Margin negative R0 resection provides the only chance for long‐term cure. Despite this, resectable disease has a 5‐year survival between 20% and 50%. Adjuvant therapy (AT) has been advocated after resected hilar cholangiocarcinoma (HC) to improve outcomes.The role of AT for resected HC is a source of significant debate. Current National Comprehensive Cancer Network (NCCN) guidelines for AT in resected HC comment that more data are necessary in order to make firm conclusions. In two recent retrospective reviews of AT in biliary tract cancer (BTC), no survival benefit was found. Conversely, within the last 10 years three single center retrospective studies have demonstrated a survival benefit with AT in resected extrahepatic cholangiocarcinoma. In the only published phase III randomized trial of AT that included patients with HC, and in the recently completed phase III trial of gemcitabine plus oxaliplatin in BTC, there was no significant survival benefit noted.Herein, we sought to determine the role of AT

Journal

Journal of Surgical OncologyWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial